U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C20H24O2
Molecular Weight 296.4034
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ETHINYL ESTRADIOL

SMILES

C[C@]12CC[C@H]3[C@@H](CCC4=CC(O)=CC=C34)[C@@H]1CC[C@@]2(O)C#C

InChI

InChIKey=BFPYWIDHMRZLRN-SLHNCBLASA-N
InChI=1S/C20H24O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,5,7,12,16-18,21-22H,4,6,8-11H2,2H3/t16-,17-,18+,19+,20+/m1/s1

HIDE SMILES / InChI
Molecular Formula C20H24O2
Molecular Weight 296.4034
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 5 / 5
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/dosage/ethinyl-estradiol-levonorgestrel.html

Ethinyl estradiol is a synthetic derivative of the natural estrogen estradiol. It is one of two estrogens currently used in oral contraceptive pills. The other, mestranol, is converted to ethinyl estradiol before it is biologically active. Ethinyl estradiol and norethindrone are used together as an oral contraceptive agent. Estrogens diffuse into their target cells and interact with a protein receptor. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Estrogens increase the hepatic synthesis of sex hormone binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins and suppress follicle-stimulating hormone (FSH) from the anterior pituitary. This cascade is initiated by initially binding to the estrogen receptors. The combination of an estrogen with a progestin suppresses the hypothalamic-pituitary system, decreasing the secretion of gonadotropin-releasing hormone (GnRH). Used for treatment of moderate to severe vasomotor symptoms associated with the menopause, female hypogonadism, prostatic carcinoma-palliative therapy of advanced disease, breast cancer, as an oral contraceptive, and as emergency contraceptive.

Originator

Schering
47
Curator's Comment: Introduced as Estinyl by Schering, US, in 1944

Approval Year

1943
64
Targets

Targets

Primary TargetPharmacologyConditionPotency
Agonist
2752
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Approved
8583
LESSINA-21

Approved Use

Indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.

Launch Date

2002
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
122.8 pg/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022262lbl.pdf
0.06 mg single, oral
dose: 0.06 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ETHINYL ESTRADIOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1335.8 pg × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022262lbl.pdf
0.06 mg single, oral
dose: 0.06 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ETHINYL ESTRADIOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
17.5 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022262lbl.pdf
0.06 mg single, oral
dose: 0.06 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ETHINYL ESTRADIOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
5 mg 1 times / day multiple, oral
Highest studied dose
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/3881294/
healthy, 14-54
Health Status: healthy
Age Group: 14-54
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/3881294/
Other AEs: Vomiting...
Other AEs:
Vomiting (23%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/3881294/
5 mg 1 times / day multiple, oral
Highest studied dose
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/3881294/
healthy, 14-54
Health Status: healthy
Age Group: 14-54
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/3881294/
Other AEs: Nausea...
Other AEs:
Nausea (48%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/3881294/
5 mg 1 times / day multiple, oral
Highest studied dose
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/3881294/
healthy, 14-54
Health Status: healthy
Age Group: 14-54
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/3881294/
Other AEs: Mastalgia...
Other AEs:
Mastalgia (32%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/3881294/
0.02 mg 1 times / day multiple, oral
Recommended
Dose: 0.02 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.02 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022262lbl.pdf
healthy, 18-41
Health Status: healthy
Age Group: 18-41
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022262lbl.pdf
Disc. AE: Dysfunctional uterine bleeding, Uterine bleeding...
AEs leading to
discontinuation/dose reduction:
Dysfunctional uterine bleeding
Uterine bleeding
Headache
Mood change
Nausea
Acne
Weight gain
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022262lbl.pdf
0.595 mg single, oral
Overdose
Dose: 0.595 mg
Route: oral
Route: single
Dose: 0.595 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/29037581
healthy, 29
Health Status: healthy
Age Group: 29
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/29037581
Disc. AE: Pulmonary embolism...
AEs leading to
discontinuation/dose reduction:
Pulmonary embolism
Sources:
https://pubmed.ncbi.nlm.nih.gov/29037581
0.02 mg 1 times / day multiple, oral
Recommended
Dose: 0.02 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.02 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022262lbl.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022262lbl.pdf
Disc. AE: Thromboembolic event, Hepatic disease...
AEs leading to
discontinuation/dose reduction:
Thromboembolic event
Hepatic disease
Headache
Hypertension
Uterine bleeding
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022262lbl.pdf
AEs

AEs

AESignificanceDosePopulation
Vomiting 23%
5 mg 1 times / day multiple, oral
Highest studied dose
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/3881294/
healthy, 14-54
Health Status: healthy
Age Group: 14-54
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/3881294/
Nausea 48%
5 mg 1 times / day multiple, oral
Highest studied dose
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/3881294/
healthy, 14-54
Health Status: healthy
Age Group: 14-54
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/3881294/
Mastalgia 32%
5 mg 1 times / day multiple, oral
Highest studied dose
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/3881294/
healthy, 14-54
Health Status: healthy
Age Group: 14-54
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/3881294/
Acne Disc. AE
0.02 mg 1 times / day multiple, oral
Recommended
Dose: 0.02 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.02 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022262lbl.pdf
healthy, 18-41
Health Status: healthy
Age Group: 18-41
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022262lbl.pdf
Dysfunctional uterine bleeding Disc. AE
0.02 mg 1 times / day multiple, oral
Recommended
Dose: 0.02 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.02 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022262lbl.pdf
healthy, 18-41
Health Status: healthy
Age Group: 18-41
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022262lbl.pdf
Headache Disc. AE
0.02 mg 1 times / day multiple, oral
Recommended
Dose: 0.02 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.02 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022262lbl.pdf
healthy, 18-41
Health Status: healthy
Age Group: 18-41
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022262lbl.pdf
Mood change Disc. AE
0.02 mg 1 times / day multiple, oral
Recommended
Dose: 0.02 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.02 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022262lbl.pdf
healthy, 18-41
Health Status: healthy
Age Group: 18-41
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022262lbl.pdf
Nausea Disc. AE
0.02 mg 1 times / day multiple, oral
Recommended
Dose: 0.02 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.02 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022262lbl.pdf
healthy, 18-41
Health Status: healthy
Age Group: 18-41
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022262lbl.pdf
Uterine bleeding Disc. AE
0.02 mg 1 times / day multiple, oral
Recommended
Dose: 0.02 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.02 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022262lbl.pdf
healthy, 18-41
Health Status: healthy
Age Group: 18-41
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022262lbl.pdf
Weight gain Disc. AE
0.02 mg 1 times / day multiple, oral
Recommended
Dose: 0.02 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.02 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022262lbl.pdf
healthy, 18-41
Health Status: healthy
Age Group: 18-41
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022262lbl.pdf
Pulmonary embolism Disc. AE
0.595 mg single, oral
Overdose
Dose: 0.595 mg
Route: oral
Route: single
Dose: 0.595 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/29037581
healthy, 29
Health Status: healthy
Age Group: 29
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/29037581
Headache Disc. AE
0.02 mg 1 times / day multiple, oral
Recommended
Dose: 0.02 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.02 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022262lbl.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022262lbl.pdf
Hepatic disease Disc. AE
0.02 mg 1 times / day multiple, oral
Recommended
Dose: 0.02 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.02 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022262lbl.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022262lbl.pdf
Hypertension Disc. AE
0.02 mg 1 times / day multiple, oral
Recommended
Dose: 0.02 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.02 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022262lbl.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022262lbl.pdf
Thromboembolic event Disc. AE
0.02 mg 1 times / day multiple, oral
Recommended
Dose: 0.02 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.02 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022262lbl.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022262lbl.pdf
Uterine bleeding Disc. AE
0.02 mg 1 times / day multiple, oral
Recommended
Dose: 0.02 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.02 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022262lbl.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022262lbl.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1946

inhibitor
2252
substrate
1193

inhibitor
2438
inhibitor
2507

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A1
132

CYP3A5
136

CYP1B1
32

CYP1A2
2153

CYP2J2
33

CYP2C19
2057

CYP2C8
1057

CYP2B6
926
P-gp
2052

UGT1A1
479

CYP1A1
389

CYP1A2
1197

CYP2C19
1119

CYP2C8
810

SULT1E1
22
CYP2A6
86

UGT
32
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP3A4
2633
 yes [IC50 1.5 uM]
CYP1A2
2333
 yes [IC50 14 uM]
yes (co-administration study)
Comment: No Preincubation; see https://pubmed.ncbi.nlm.nih.gov/17253885/ for list of DDI
Page: 4.0
CYP2J2
36
 yes [IC50 15 uM]
CYP2B6
1160
 yes [IC50 19 uM]
yes (co-administration study)
Comment: No Preincubation; see https://pubmed.ncbi.nlm.nih.gov/17253885/ for list of DDI
Page: 4.0
CYP1A1
272
 yes [IC50 2.1 uM]
CYP2C19
2141
 yes [IC50 2.8 uM]
yes (co-administration study)
Comment: No Preincubation; see https://pubmed.ncbi.nlm.nih.gov/17253885/ for list of DDI
Page: 4.0
CYP2D6
2546
 yes [IC50 24 uM]
CYP3A5
201
 yes [IC50 3.3 uM]
CYP2C8
1117
 yes [IC50 8.3 uM]
CYP1B1
93
 yes [IC50 9.2 uM]
CYP2C9
2497
 yes [IC50 9.2 uM]
CYP2A6
911
 yes
weak (co-administration study)
Comment: ~22% increase in clerance of nicotine
Page: 12.0
UGT
70
 yes
yes (co-administration study)
Comment: Coadministration with propranolol: ~70% increase in glucuronidation; Coadministration with lamotrigine: ~64% increase in glucuronidation
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP2C9
1193
 major
CYP3A4
1946
 major
yes (co-administration study)
Comment: see https://pubmed.ncbi.nlm.nih.gov/17253885/ for list of DDI
CYP1A2
1197
 minor
CYP2C19
1119
 minor
CYP2C8
810
 minor
CYP1A1
389
 yes
P-gp
2052
 yes
SULT1E1
22
 yes
UGT1A1
479
 yes
yes (co-administration study)
Comment: see https://pubmed.ncbi.nlm.nih.gov/17253885/ for list of DDI
Sourcing

Sourcing

Vendor/AggregatorIDURL
AA Blocks
AA00IKFM
https://www.aablocks.com/goods/Goods/detail?id=AA00IKFM
Aaron Chemicals
AR00IL7E
http://www.aaronchem.com/57-63-6
abcr GmbH
AB250062
http://www.abcr.com/shop/en/AB250062
AbMole Bioscience
M3392
http://www.abmole.com/products/ethinyl-estradiol.html
Achemtek
0104-003558
http://www.achemtek.com/57-63-6
Acorn PharmaTech
ACN-032019
http://www.acornpharmatech.com/
Acros Organics
AC461550010
https://www.fishersci.com/shop/products/ethinylestradiol-98-acros-organics-1/AC461550010
Acros Organics
AC461550050
https://www.fishersci.com/shop/products/ethinylestradiol-98-acros-organics/AC461550050
AHH Chemical co.,ltd
API-1859
http://www.ahhchemical.com/product/API-1859.html
AK Scientific, Inc. (AKSCI)
H075
http://www.aksci.com/item_detail.php?cat=H075
Alsachim
1652
http://www.alsachim.com/product-C2921-glo.bal-view.html
Ambeed
A638512
https://www.ambeed.com/products/57-63-6.html
ApexBio Technology
A8428
http://www.apexbt.com/ethinyl-estradiol-22538.html
Aurora Fine Chemicals LLC
A13.142.519
http://online.aurorafinechemicals.com/info?ID=A13.142.519
AvaChem Scientific
4551
http://www.avachem.com/productSearch.asp?4551
Avantor Inc
101094-964
https://us.vwr.com/store/catalog/product.jsp?catalog_number=101094-964
BioCrick
BCC3777
http://www.biocrick.com/Ethinyl-Estradiol-BCC3777.html
BioSynth
Q-201076
https://www.biosynth.com/en/products/life-science/other-biochemicals/products/Q-201076.html
BLD Pharm
BD34146
http://www.bldpharm.com/products/57-63-6.html
Chem Scene
CS-2161
http://www.chemscene.com/57-63-6.html
Chemenu
CM110268
http://www.chemenu.com/products/CM110268
ChemMol
30103882
http://www.chemmol.com/chemmol/30103882.html
Chemspace
CSSB00000693938
https://chem-space.com/CSSB00000693938
CSNpharm
CSN16404
https://www.csnpharm.com/products/ethynyl-estradiol.html
DC Chemicals
DC31684
http://www.dcchemicals.com//product_show-Ethinyl_Estradiol.html
Enamine
Z1541638513
https://www.enaminestore.com/catalog/Z1541638513
FondChemical
FDB-2951
http://www.fondchemical.com/cpshow_cid_8_pid_2219.html
Glentham Life Sciences
GP3324
http://www.glentham.com/products/product/GP3324/
Hairui
HR138945
http://www.hairuichem.com/en/product/57-63-6.html
iChemical
EBD2157852
http://www.ichemical.com/products/57-63-6.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
Lab Network
LN00243285
https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00243285
LGC Standards
DRE-C13245100
https://www.lgcstandards.com/US/en/p/DRE-C13245100
LGC Standards
DRE-XA13245100AL
https://www.lgcstandards.com/US/en/p/DRE-XA13245100AL
LGC Standards
LGCFOR0123.00
https://www.lgcstandards.com/US/en/p/LGCFOR0123.00
LGC Standards
MM0123.00-0250
https://www.lgcstandards.com/US/en/p/MM0123.00-0250
mcule
MCULE-5991854877
https://mcule.com/MCULE-5991854877/
MedChem Express
HY-B0216
https://www.medchemexpress.com/Ethynyl-Estradiol.html
MuseChem
A000604
https://www.musechem.com/product/A000604.html
OChem
10156
http://www.ocheminc.com/index.php?act=psearch&pid=003E690
Parchem
28897
http://www.parchem.com/chemical-supplier-distributor/Ethinyl-Estradiol-018897.aspx
Selleck Chemicals
S1625
http://www.selleckchem.com/products/Ethinyl-Estradiol.html
Sigma-Aldrich
02463_SIAL
https://www.sigmaaldrich.com/catalog/product/sial/02463?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich
1260001_USP
https://www.sigmaaldrich.com/catalog/product/usp/1260001?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich
46263_SIAL
https://www.sigmaaldrich.com/catalog/product/sial/46263?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich
E1900000_SIAL
https://www.sigmaaldrich.com/catalog/product/sial/e1900000?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich
E4876_SIGMA
https://www.sigmaaldrich.com/catalog/product/sigma/e4876?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Smolecule
S527465
http://www.smolecule.com/products/s527465
Smolecule
S527518
http://www.smolecule.com/products/s527518
THE BioTek
bt-267774
https://www.thebiotek.com/product/inhibitors/bt-267774
THE BioTek
bt-267827
https://www.thebiotek.com/product/inhibitors/bt-267827
VladaChem
VL274269-1G
https://www.vladachem.com/product.php?products=57-63-6
Yuhao Chemical
RT19571
http://www.chemyuhao.com/57-63-6.html
PubMed

PubMed

TitleDatePubMed
Effect of epomediol on ethinyloestradiol-induced changes in bile acid and cholesterol metabolism in rats.
2001-08
Regulation of sex hormone-binding globulin secretion in human hepatoma G2 cells.
2001-08
Estrogen-derived steroidal metal complexes: agents for cellular delivery of metal centers to estrogen receptor-positive cells.
2001-07-30
A scheme of combined oral contraceptives for women more than 40 years old.
2001-07-13
Development and validation of a homologous zebrafish (Danio rerio Hamilton-Buchanan) vitellogenin enzyme-linked immunosorbent assay (ELISA) and its application for studies on estrogenic chemicals.
2001-07
Lack of gender differences and large intrasubject variability in cytochrome P450 activity measured by phenotyping with dextromethorphan.
2001-07
Effect of a combined oral contraceptive containing 3 mg of drospirenone and 30 microg of ethinyl estradiol on the human endometrium.
2001-07
Enhancement of splenic-macrophage Fcgamma receptor expression by treatment with estrogens.
2001-07
Ovarian and endometrial function during hormonal contraception.
2001-07
Molecular basis of perinatal changes in UDP-glucuronosyltransferase activity in maternal rat liver.
2001-07
Survival and precopulatory behaviour of Gammarus pulex (L.) exposed to two xenoestrogens.
2001-07
Determination of estrogens in river water by gas chromatography-negative-ion chemical-ionization mass spectrometry.
2001-06-15
Neonatal exposure to potent and environmental oestrogens and abnormalities of the male reproductive system in the rat: evidence for importance of the androgen-oestrogen balance and assessment of the relevance to man.
2001-06-08
Pubertal disorders in inv dup(15) syndrome.
2001-06
Protein S levels are lower in women receiving desogestrel-containing combined oral contraceptives (COCs) than in women receiving levonorgestrel-containing COCs at steady state and on cross-over.
2001-06
Lack of effect of rosiglitazone on the pharmacokinetics of oral contraceptives in healthy female volunteers.
2001-06
Effects of the synthetic estrogen 17 alpha-ethinylestradiol on the life-cycle of the fathead minnow (Pimephales promelas).
2001-06
Breast cancer and HRT--what are the data?
2001-05-26
Effects of binary mixtures of six xenobiotics on hormone concentrations and morphometric endpoints of northern bobwhite quail (Colinus virginianus).
2001-05-25
Diane 35 and spironolactone combination in the treatment of hirsutism.
2001-05
Testosterone 5alpha-reductase inhibitory active constituents from Anemarrhenae Rhizoma.
2001-05
Streamlined beta-galactosidase assay for analysis of recombinant yeast response to estrogens.
2001-05
Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition.
2001-05
Assessment of oestrogenic potency of chemicals used as growth promoter by in-vitro methods.
2001-05
Phytoestrogens and carcinogenesis-differential effects of genistein in experimental models of normal and malignant rat endometrium.
2001-05
Altered prostate growth and daily sperm production in male mice exposed prenatally to subclinical doses of 17alpha-ethinyl oestradiol.
2001-05
Preventive effects of a Chinese herbal medicine, hochu-ekki-to, on bone loss in ovariectomized rats.
2001-04-05
Synthetic estrogens-mediated activation of JNK intracellular signaling molecule.
2001-04
Low dosage monophasic oral contraceptive use and intermittent exercise performance and metabolism in humans.
2001-04
High metabolization of catecholestrogens by type 1 estrogen sulfotransferase (hEST1).
2001-04
Oestrogens and oestrogenic activity in raw and treated water in Severn Trent Water.
2001-04
Exposure of Chironomus riparius larvae to 17alpha-ethynylestradiol: effects on survival and mouthpart deformities.
2001-03-26
Determination of steroid sex hormones and related synthetic compounds considered as endocrine disrupters in water by fully automated on-line solid-phase extraction-liquid chromatography-diode array detection.
2001-03-16
Clinical recommendations for oxcarbazepine.
2001-03
Mechanism of action of hormonal preparations used for emergency contraception: a review of the literature.
2001-03
Applicability of micellar electrokinetic chromatography to the analysis of estrogens in water.
2001-03
Comparison of the effect on acne with a combiphasic desogestrel-containing oral contraceptive and a preparation containing cyproterone acetate.
2001-03
Practices of prescribing oral contraceptives in Poland.
2001-03
[Comparison of 2 therapeutic strategies in severe endometriosis, in young women consulting for sterility or pain. II. In the case of infertility, value of ovarian stimulation with intrauterine insemination after surgery].
2001-03
Effectiveness of emergency contraceptive pills between 72 and 120 hours after unprotected sexual intercourse.
2001-03
Fine structure of prolactin cell of female albino rat as affected by some antifertility drugs--a comparative electron microscopic study.
2001-02
Metabolism of chylomicron cholesterol is delayed by estrogen. An in vivo study in the rat.
2001-02
Minimal androgenic activity of a new oral contraceptive containing norethindrone acetate and graduated doses of ethinyl estradiol.
2001-02
[Comparison of 2 therapeutic strategies for severe endometriosis, in young women counsulting for sterility or pain. Results in cases of chronic pelvic pain].
2001-02
Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers.
2001-02
Effects of age and weaning on the immature rat uterotrophic assay using ethynylestradiol.
2001-01
Influence of low-dose oral contraceptives, alcohol, and grapefruit on.
2001-01
Lack of effect of alcohol on ethinylestradiol in premenopausal women.
2001-01
Method for non-invasively recording electrocardiograms in conscious mice.
2001
Biphasic versus monophasic oral contraceptives for contraception.
2001
Patents

Patents

20010002262
19
20010018073
2
JP2001328998A
1
JP2002145759A
5
JP2002543154A
5
JP2002543158A
5
JP2004520375A
3
JP2007197459A
1
JP2007512291A
11
JP2009102424A
1
JP3534775B2
2
JPH0873328A
1
JPS61251606A
1

Sample Use Guides

In Vivo Use Guide
Usual Adult Dose for Endometriosis Ethinyl estradiol-levonorgestrel products are packaged in 21 or 28 day dosage preparations. The last seven tablets in 28 day dosage preparations are hormonally inert. Regardless of the number of tablets in a package, the cycle length for oral contraceptives is generally considered to be 28 days.
Route of Administration: Oral
In Vitro Use Guide
EE (
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:54:27 GMT 2025
Edited
by admin
on Mon Mar 31 17:54:27 GMT 2025
Record UNII
423D2T571U
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ETHINYL ESTRADIOL
EMA EPAR   HSDB   MI   ORANGE BOOK   USP   USP-RS   VANDF  
Common Name English
ETHINYLESTRADIOL
EP   INCI   INN   MART.   WHO-DD   WHO-IP  
INCI   INN  
Preferred Name English
ORSYTHIA COMPONENT ETHINYL ESTRADIOL
Common Name English
OVRAL COMPONENT ETHINYL ESTRADIOL
Common Name English
ETHINYL ESTRADIOL [VANDF]
Common Name English
FEMCON FE COMPONENT ETHINYL ESTRADIOL
Common Name English
MINASTRIN 24 FE COMPONENT ETHINYL ESTRADIOL
Brand Name English
MARLISSA COMPONENT ETHINYL ESTRADIOL
Brand Name English
ISIBLOOM COMPONENT ETHINYL ESTRADIOL
Brand Name English
KELNOR COMPONENT ETHINYL ESTRADIOL
Common Name English
ZOVIA COMPONENT ETHINYL ESTRADIOL
Brand Name English
AVIANE COMPONENT ETHINYL ESTRADIOL
Brand Name English
QUARTETTE COMPONENT ETHINYL ESTRADIOL
Brand Name English
ETHINYL ESTRADIOL [HSDB]
Common Name English
ETHINYL ESTRADIOL [USP-RS]
Common Name English
NSC-10973
Code English
ELIFEMME COMPONENT ETHINYL ESTRADIOL
Brand Name English
LYNORAL
Brand Name English
KURVELO COMPONENT ETHINYL ESTRADIOL
Common Name English
SEASONIQUE COMPONENT ETHINYL ESTRADIOL
Common Name English
ORTHO TRI-CYCLEN COMPONENT ETHINYL ESTRADIOL
Common Name English
NORQUEST FE COMPONENT ETHINYL ESTRADIOL
Common Name English
PREVIFEM COMPONENT ETHINYL ESTRADIOL
Common Name English
YAZ COMPONENT ETHINYL ESTRADIOL
Common Name English
ETHINYL ESTRADIOL [MI]
Common Name English
LYBREL COMPONENT ETHINYL ESTRADIOL
Common Name English
BEYAZ COMPONENT ETHINYL ESTRADIOL
Common Name English
TRI-SPRINTEC COMPONENT ETHINYL ESTRADIOL
Common Name English
ETHINYL ESTRADIOL [EMA EPAR]
Common Name English
SPRINTEC COMPONENT ETHINYL ESTRADIOL
Common Name English
ETHINYLESTRADIOLUM [WHO-IP LATIN]
Common Name English
CYCLESSA COMPONENT ETHINYL ESTRADIOL
Common Name English
ESTROSTEP FE COMPONENT ETHINYL ESTRADIOL
Common Name English
PORTIA COMPONENT ETHINYL ESTRADIOL
Brand Name English
ETHINYLESTRADIOL [EP MONOGRAPH]
Common Name English
LEVORA COMPONENT ETHINYL ESTRADIOL
Brand Name English
ENSKYCE COMPONENT ETHINYL ESTRADIOL
Brand Name English
TWIRLA COMPONENT ETHINYL ESTRADIOL
Brand Name English
17-ETHINYLESTRADIOL
Common Name English
ARANELLE COMPONENT ETHINYL ESTRADIOL
Common Name English
ETHINYLESTRADIOL [MART.]
Common Name English
NORDETTE COMPONENT ETHINYL ESTRADIOL
Brand Name English
XULANE COMPONENT ETHINYL ESTRADIOL
Brand Name English
ESTINYL
Brand Name English
ETHINYLESTRADIOL [JAN]
Common Name English
QUASENSE COMPONENT ETHINYL ESTRADIOL
Common Name English
TAYTULLA COMPONENT ETHINYL ESTRADIOL
Brand Name English
ethinylestradiol [INN]
Common Name English
ETHINYLOESTRADIOL
Common Name English
PIMTREA COMPONENT ETHINYL ESTRADIOL
Brand Name English
SAFYRAL COMPONENT ETHINYL ESTRADIOL
Common Name English
INTROVALE COMPONENT ETHINYL ESTRADIOL
Common Name English
TRIVORA COMPONENT ETHINYL ESTRADIOL
Brand Name English
KARIVA COMPONENT ETHINYL ESTRADIOL
Common Name English
ORTHO-CEPT COMPONENT ETHINYL ESTRADIOL
Common Name English
LO MINASTRIN FE COMPONENT ETHINYL ESTRADIOL
Brand Name English
FEMINONE
Brand Name English
TRI-PREVIFEM COMPONENT ETHINYL ESTRADIOL
Common Name English
YASMIN COMPONENT ETHINYL ESTRADIOL
Common Name English
NUVARING COMPONENT ETHINYL ESTRADIOL
Common Name English
TRI LO SPRINTEC COMPONENT ETHINYL ESTRADIOL
Common Name English
ANNOVERA COMPONENT ETHINYL ESTRADIOL
Brand Name English
ALTAVERA COMPONENT ETHINYL ESTRADIOL
Common Name English
MIRCETTE COMPONENT ETHINYL ESTRADIOL
Common Name English
VYFEMLA COMPONENT ETHINYL ESTRADIOL
Brand Name English
LO LOESTRIN FE COMPONENT ETHINYL ESTRADIOL
Common Name English
ETHINYL ESTRADIOL [ORANGE BOOK]
Common Name English
ENPRESSE COMPONENT ETHINYL ESTRADIOL
Brand Name English
ALESSE COMPONENT ETHINYL ESTRADIOL
Common Name English
CRYSELLE COMPONENT ETHINYL ESTRADIOL
Common Name English
ETHINYLESTRADIOL [WHO-IP]
Common Name English
LEVLITE COMPONENT ETHINYL ESTRADIOL
Common Name English
SETLAKIN COMPONENT ETHINYL ESTRADIOL
Brand Name English
VOLNEA COMPONENT ETHINYL ESTRADIOL
Brand Name English
DESOGEN COMPONENT ETHINYL ESTRADIOL
Common Name English
VELIVET COMPONENT ETHINYL ESTRADIOL
Common Name English
17ALPHA-ETHINYLESTRADIOL
Common Name English
PREVEN COMPONENT ETHINYL ESTRADIOL
Common Name English
LOSEASONIQUE COMPONENT ETHINYL ESTRADIOL
Common Name English
VIENVA COMPONENT ETHINYL ESTRADIOL
Brand Name English
19-Nor-17?-pregna-1,3,5(10)-trien-20-yne-3,17-diol
Common Name English
Ethinylestradiol [WHO-DD]
Common Name English
TRI-LEGEST FE COMPONENT ETHINYL ESTRADIOL
Common Name English
FEMHRT COMPONENT ETHINYL ESTRADIOL
Common Name English
LESSINA COMPONENT ETHINYL ESTRADIOL
Brand Name English
BEKYREE COMPONENT ETHINYL ESTRADIOL
Brand Name English
SEASONALE COMPONENT ETHINYL ESTRADIOL
Common Name English
TRIPHASIL COMPONENT ETHINYL ESTRADIOL
Brand Name English
VIORELE COMPONENT ETHINYL ESTRADIOL
Brand Name English
NORINYL COMPONENT ETHINYL ESTRADIOL
Brand Name English
19-NORPREGNA-1,3,5(10)-TRIEN-20-YNE-3,17-DIOL, (17.ALPHA.)-
Common Name English
BREVICON COMPONENT ETHINYL ESTRADIOL
Brand Name English
FEMLYV COMPONENT ETHINYL ESTRADIOL
Brand Name English
LEVONEST COMPONENT ETHINYL ESTRADIOL
Common Name English
ETHINYL ESTRADIOL [USP MONOGRAPH]
Common Name English
Classification Tree Code System Code
WHO-VATC QG03AA06
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
NDF-RT N0000000100
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
WHO-ESSENTIAL MEDICINES LIST 18.3.1 (ETH/LEV)
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
WHO-VATC QG03AB03
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
WHO-ATC G03AA02
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
WHO-ATC G03AB05
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
WHO-VATC QG03AA07
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
WHO-ATC G03AA13
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
WHO-VATC QG03AB07
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
WHO-ATC G03AA10
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
WHO-ATC G03AB01
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
WHO-ATC G03CA01
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
WHO-ATC G03AA07
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
WHO-VATC QL02AA03
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
NDF-RT N0000175825
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
WHO-VATC QG03AA03
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
WHO-ATC G03AA15
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
WHO-VATC QG03AA04
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
WHO-ESSENTIAL MEDICINES LIST 18.3.1 (ETH/NOR)
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
WHO-VATC QG03AB01
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
NCI_THESAURUS C478
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
WHO-ATC G03AA12
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
WHO-ATC G03AA16
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
WHO-VATC QG03AA12
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
WHO-ATC G03AA05
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
WHO-ATC G03AA08
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
WHO-ATC G03AA04
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
WHO-VATC QG03CA01
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
WHO-ATC G03AB04
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
WHO-ATC G03AB06
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
WHO-VATC QG03AA05
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
WHO-VATC QG03AA01
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
WHO-VATC QG03AA09
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
WHO-ATC G03AA06
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
WHO-VATC QG03AA10
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
WHO-ATC G03AB03
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
WHO-VATC QG03AA02
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
FDA ORPHAN DRUG 28788
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
WHO-VATC QG03AA08
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
WHO-VATC QG03AB05
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
WHO-ATC G03AB07
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
LIVERTOX 382
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
WHO-VATC QG03AB04
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
WHO-ATC G03AA11
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
WHO-VATC QG03AA13
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
WHO-VATC QG03AA16
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
WHO-VATC QG03AA15
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
WHO-ATC G03AA03
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
WHO-ATC G03AA09
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
WHO-VATC QG03AB02
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
WHO-ATC G03AA01
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
WHO-VATC QG03AB06
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
EMA ASSESSMENT REPORTS EVRA (AUTHORIZED: CONTRACEPTION)
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
WHO-VATC QG03AA11
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
WHO-ATC G03AB02
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
WHO-ATC L02AA03
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
Code System Code Type Description
EVMPD
SUB07277MIG
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
PRIMARY
DAILYMED
423D2T571U
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
PRIMARY
FDA UNII
423D2T571U
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
PRIMARY
PUBCHEM
5991
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
PRIMARY
RS_ITEM_NUM
1260001
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
PRIMARY
NCI_THESAURUS
C486
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
ETHINYL ESTRADIOL
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
PRIMARY Description: A white to slightly yellowish white, crystalline powder; odourless.Solubility: Practically insoluble in water; freely soluble in ethanol (~750 g/l) TS; soluble in acetone R and dioxan R.Category: Estrogen.Storage: Ethinylestradiol should be kept in a well-closed container, protected from light.Additional information: Ethinylestradiol may exist in 2 polymorphic forms one of which melts at about 183?C, the other, metastable, at about 143?C.RequirementsDefinition: Ethinylestradiol contains not less than 97.0% and not more than 102.0% of C20H24O2, calculated with reference to the dried substance.
CHEBI
4903
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
PRIMARY
NSC
10973
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
PRIMARY
SMS_ID
100000091721
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
PRIMARY
ChEMBL
CHEMBL691
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
PRIMARY
DRUG BANK
DB00977
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
PRIMARY
MERCK INDEX
m5058
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
PRIMARY Merck Index
MESH
D004997
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
PRIMARY
LACTMED
Ethinyl Estradiol
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
PRIMARY
EPA CompTox
DTXSID5020576
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
PRIMARY
ECHA (EC/EINECS)
200-342-2
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
PRIMARY
RXCUI
4124
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
PRIMARY RxNorm
INN
437
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
PRIMARY
IUPHAR
7071
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
PRIMARY
DRUG CENTRAL
1082
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
PRIMARY
CAS
57-63-6
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
PRIMARY
HSDB
3587
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
PRIMARY
WIKIPEDIA
ETHINYL ESTRADIOL
Created by admin on Mon Mar 31 17:54:27 GMT 2025 , Edited by admin on Mon Mar 31 17:54:27 GMT 2025
PRIMARY
Related Record Type Details
Structure of ETHINYL ESTRADIOL
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
CYTOCHROME P450 3A4
METABOLIC ENZYME -> SUBSTRATE
MAJOR
ALDEHYDE OXIDASE
METABOLIC ENZYME -> INHIBITOR
IC50
CYTOCHROME P450 2C8
METABOLIC ENZYME -> SUBSTRATE
Structure of ETHYNYL ESTRADIOL 17-SULFATE
DERIVATIVE -> PARENT
CYTOCHROME P450 2C9
METABOLIC ENZYME -> SUBSTRATE
MAJOR
Structure of ETHINYL ESTRADIOL
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
EP
CYTOCHROME P450 1A2
METABOLIC ENZYME -> SUBSTRATE
CYTOCHROME P450 2C19
METABOLIC ENZYME -> SUBSTRATE
Related Record Type Details
Structure of ETHYNYLESTRADIOL-3-O-GLUCURONIDE
METABOLITE -> PARENT
MAJOR
URINE
Structure of 10.BETA.-HYDROXY-19-NORETHISTERONE
METABOLITE -> PARENT
Structure of 2-HYDROXYETHINYLESTRADIOL
METABOLITE -> PARENT
Structure of ETHYNYLESTRADIOL 3-SULFATE
METABOLITE -> PARENT
MAJOR
PLASMA
Structure of MESTRANOL
PRODRUG -> METABOLITE ACTIVE
Related Record Type Details
Structure of 9,11-DEHYDRO ETHYNYL ESTRADIOL
IMPURITY -> PARENT
For the calculation of contents, multiply the peak areas by 0.7
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 6.BETA.-HYDROXY-ETHINYLESTRADIOL
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of ALFATRADIOL
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of ESTRADIOL
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 4-METHYL-ETHINYLESTRADIOL
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 1-METHYL-ETHINYLESTRADIOL
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 6-OXO-ETHINYLESTRADIOL
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 6,7-DEHYDROETHYNYLESTRADIOL
IMPURITY -> PARENT
For the calculation of contents, multiply the peak areas by 0.4
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 17.BETA.-ETHINYLESTRADIOL
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 6.ALPHA.-HYDROXY-ETHINYLESTRADIOL
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 2-METHYL-ETHINYLESTRADIOL
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 16-OXO-ETHINYLESTRADIOL
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of ESTRONE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
Structure of ETHINYL ESTRADIOL
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966